Oxford Immunotec Global (OXFD) Receiving Somewhat Positive News Coverage, Study Finds
News coverage about Oxford Immunotec Global (NASDAQ:OXFD) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.8774269657732 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit (reuters.com)
- Oxford Immunotec Global (OXFD) Lifted to Hold at BidaskClub (americanbankingnews.com)
- QIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit (finance.yahoo.com)
- Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit (finance.yahoo.com)
OXFD has been the topic of a number of analyst reports. BidaskClub cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. BTIG Research initiated coverage on Oxford Immunotec Global in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 price target on the stock. Zacks Investment Research upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Cowen restated a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. Finally, ValuEngine cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Oxford Immunotec Global presently has a consensus rating of “Hold” and an average price target of $19.75.
In other news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the sale, the director now owns 17,778 shares in the company, valued at $237,336.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/oxford-immunotec-global-oxfd-receiving-somewhat-positive-news-coverage-study-finds/1772504.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.